SciClone Pharmaceuticals Executives

SciClone Pharmaceuticals employs about 590 people. The company is managed by 13 executives with a total tenure of roughly 153 years, averaging almost 11.0 years of service per executive, having 45.38 employees per reported executive. Analysis of SciClone Pharmaceuticals' management performance can provide insight into the firm performance.
Hong Zhao  CEO
CEO of China Operations
Friedhelm Blobel  CEO
CEO and President Executive Director and Member of Bus. Devel. Committee
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

SciClone Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 25.82 %, which suggests for every 100 dollars of sales, it generated a net operating income of $25.82.

SciClone Pharmaceuticals Notable Stakeholders

A SciClone Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SciClone Pharmaceuticals often face trade-offs trying to please all of them. SciClone Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SciClone Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hong ZhaoCEO of China OperationsProfile
Friedhelm BlobelCEO and President Executive Director and Member of Bus. Devel. CommitteeProfile
Jon SaxeIndependent Chairman of the BoardProfile
Raymond LowVice President - Finance, ControllerProfile
Robert KingSenior Vice President - Product Development and Supply ChainProfile
Wilson CheungCFO, Sr. VP of Fin. and SecretaryProfile
Lan XieVP of Fin. and CFO of China OperationsProfile
Richard HawkinsIndependent DirectorProfile
Gregg LapointeIndependent DirectorProfile
Nancy ChangDirectorProfile
Anthony LapointeIndependent DirectorProfile
Simon LiIndependent DirectorProfile
Charles MengVP of Compliance and General CounselProfile

SciClone Pharmaceuticals Workforce Analysis

Traditionally, organizations such as SciClone Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SciClone Pharmaceuticals within its industry.

SciClone Pharmaceuticals Manpower Efficiency

Return on SciClone Pharmaceuticals Manpower

Revenue Per Employee291.6K
Revenue Per Executive13.2M
Net Income Per Employee73.4K
Net Income Per Executive3.3M
Working Capital Per Employee223.2K
Working Capital Per Executive10.1M
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in SciClone Stock

If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Correlations
Find global opportunities by holding instruments from different markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance